A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.

Conditions

What is the purpose of this trial?

To determine the efficacy by progression free survival (using blinded independent central

review according to modified RECIST 1.1) of olaparib maintenance monotherapy compared

to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical

complete response or partial response following first line platinum based chemotherapy.


Participation Guidelines

Age:
Gender:

Click here for detailed information about who can participate in this trial.


Sponsor:
Astra Zeneca, L.P.
Dates:
02/19/2014
Last Updated:
Study HIC#:
1311013093